Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 516 • 2017 ACR/ARHP Annual Meeting
Efficacy of Adding Iguratimod Therapy in Rheumatoid Arthritis　Patients Who Had Inadequate Response to Biologic Dmards
Toshiaki Miyamoto, Rheumatology, SEIREI HAMAMATSU GENERAL HOSPITAL, Hamamatsu, Japan
Background/Purpose: Iguratimod (IGU) was approved in June 2012 and recommended by JCR guideline 2014 in the treatment of rheumatoid arthritis (RA). Although there have been…
Abstract Number: 863 • 2017 ACR/ARHP Annual Meeting
Functionally Distinct Pathogenic Subsets of Fibroblasts Exist within the Inflamed Synovial Membrane and Mediate Specific Aspects of Inflammatory Disease Pathology
Adam Paul Croft¹, Joana Campos², Loriane Savary², Emma Bishop², Jason Turner¹, Guillaume Desanti², Francesca Barone³, Andrew Filer³ and Chris Buckley², ¹Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ²University of Birmingham, Birmingham, United Kingdom, ³Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Fibroblasts are key effector cells in the persistence of synovial inflammation and joint damage. It is not yet known whether specific subsets of synovial…
Abstract Number: 1030 • 2017 ACR/ARHP Annual Meeting
Healthcare Service Utilization and Costs of Certolizumab Pegol Versus Infliximab Treatment in Patients with Rheumatoid Arthritis
Joseph Tkacz¹, Edward Lee², Robert Low², Jeffrey Stark², Mohamed Yassine² and Brenna Brady¹, ¹Health Analytics LLC, Columbia, MD, ²UCB Pharma, Smyrna, GA
Background/Purpose: Prior retrospective claims analyses examining rheumatoid arthritis (RA) treatment costs have shown infliximab (IFX) to be costlier than certolizumab pegol (CZP) across all sites…
Abstract Number: 2635 • 2016 ACR/ARHP Annual Meeting
Using Patient Reported Outcomes to Inform a Treat to Target Treatment Approach in RA
Eric M. Ruderman¹, Jennifer Beaumont², Emily Bacalao¹, George J. Greene², Azra Muftic² and David Cella², ¹Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: The Patient Reported Outcomes Measurement Information System (PROMIS) is an NIH initiative to develop patient-reported outcome measures (PROs) for use across chronic conditions. PROMIS…
Abstract Number: 2636 • 2016 ACR/ARHP Annual Meeting
No Strong Evidence Supporting Predictors for Successful Dose Reduction or Discontinuation of a Biologic in Rheumatoid Arthritis: A Systematic Review
L. Tweehuysen¹, C.H. van den Ende², F.M.M. Beeren², E.M.J. Been², F.H.J. van den Hoogen^3,4 and A.A. den Broeder³, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ³Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Rheumatology, Radboudumc, Nijmegen, Netherlands
Background/Purpose: Tapering of biologics in rheumatoid arthritis (RA) is based on a trial-and-error disease activity guided strategy, because it is not known in advance which…
Abstract Number: 2649 • 2016 ACR/ARHP Annual Meeting
Patient Preferences Regarding Rheumatoid Arthritis Therapies in Lebanon: Results from a National, Multicenter, Cross-Sectional Survey
Fouad Fayad¹, Nelly Ziade², Georges Merheb^3,4, Said Attoui⁵, Alla Aiko⁶, Kamel Mroue⁵ and Abdel Fattah Masri⁷, ¹Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ²Rheumatology, Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ³Internal Medicine, Notre Dame des Secours University Hospital, Jbeil, Lebanon, ⁴Holly Spirit University, Kaslik, Lebanon, ⁵Hammoud University Medical Center, Saida, Lebanon, ⁶Saint Georges Hospital, Beirut, Lebanon, ⁷American University of Beirut Medical Center, Beirut, Lebanon
Background/Purpose: Treatment options in rheumatoid arthritis (RA) have expanded significantly over recent years, and several agents are now available for oral, subcutaneous (SC) or intravenous…
Abstract Number: 607 • 2016 ACR/ARHP Annual Meeting
The Clinical Response to Biologic and Non-Biologic Disease Modifying Antirheumatic Drugs (DMARDs) According to Gender in a French-Canadian Population with Rheumatoid Arthritis (RA)
Sonia Lagacé¹, Louis Bessette^2,3, Louis Coupal⁴ and Denis Choquette⁴, ¹Medicine, Laval University, Quebec, QC, Canada, ²Rheumatology, Laval University, Québec, QC, Canada, ³Rhumatologie, CHU de Québec - Université Laval, Quebec, QC, Canada, ⁴Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: Several studies have reported that women with RA had higher level of pain, disease activity and functional impairment compared to men. In addition, women…
Abstract Number: 2653 • 2016 ACR/ARHP Annual Meeting
Results of a Comprehensive Review of Pulmonary Function and Safety Data in a Phase IIb Clinical Program Testing Anti-GM-CSF Receptor Antagonist Mavrilimumab for Treatment of RA
GR Burmester¹, MA Michaels², D Close³, A Godwood³, K Middleton³, P Miranda⁴, J Vencovský⁵, JM Kremer⁶, IB McInnes⁷, M Albulescu^³ and Michael Weinblatt⁸, ¹Charité – University Medicine Berlin, Berlin, Germany, ²MedImmune, Gaithersburg, MD, ³MedImmune, Cambridge, United Kingdom, ⁴Centro De Estudios Reumatológicos, Santiago, Chile, ⁵Charles University, Prague, Czech Republic, ⁶The Albany Medical College, Albany, NY, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Brigham and Women’s Hospital, Boston, MA
Background/Purpose: RA is associated with significant pulmonary comorbidity and declines in lung function over time; but longitudinal assessment of pulmonary abnormalities in the context of…
Abstract Number: 610 • 2016 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis of Comparative Efficacy of Biologics in Treating Patients with Rheumatoid Arthritis: Assessment of Long-Term Radiographic Progression from Published Clinical Trials
Erin Murray¹, Yekaterina Butylkova¹, Alexandra Ellis¹, Martha Skup², Jasmina Kalabic³ and Vishvas Garg⁴, ¹Doctor Evidence, Santa Monica, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁴AbbVie Inc, North Chicago, IL
Background/Purpose: Previously, several studies have meta-analyzed clinical, functional or structural efficacy of biologics in treating rheumatoid arthritis (RA) patients. However, the comparative efficacy of biologics…
Abstract Number: 3094 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Initial or Subsequent Choice of Biologic Disease Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis
Yinzhu Jin¹, Rishi J. Desai¹, Jun Liu¹, Nam-Kyong Choi¹ and Seoyoung Kim^2,3, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospita and, Harvard Medical School,, Boston, MA
Background/Purpose: Treatment with disease-modifying antirheumatic drugs (DMARDs) is considered the standard of care for rheumatoid arthritis (RA). Over the past two decades, major advances have…
Abstract Number: 637 • 2016 ACR/ARHP Annual Meeting
Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs
Natalie Boytsov¹, George W. Reed², Leslie R Harrold^2,3, Xiang Zhang¹, Carol L Gaich¹, Cynthia J Larmore¹, Ying Shan², S Rebello⁴ and Andre B. Araujo¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Corrona, LLC, Southborough, MA, ³UMass Medical School, Worcester, MA, ⁴Epidemiology, Corrona, Southborough, MA
Background/Purpose: The purpose of this study was to describe biologic initiation patterns over a 1-year follow-up period in rheumatoid arthritis (RA) patients with moderate…
Abstract Number: 3212 • 2016 ACR/ARHP Annual Meeting
Treat-to-Target in RA: Does Early Simplified Disease Activity Index (SDAI) Remission Lead to Better 5-Year Functional Outcomes Than SDAI Low Disease Activity?
Vibeke Norvang, Elisabeth Lie, Inge C Olsen, Eirik K Kristianslund, Tore K Kvien and Till Uhlig, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The management of rheumatoid arthritis (RA) has evolved considerably during the last couple of decades, with current recommended practice being a treat-to-target approach, involving…
Abstract Number: 1540 • 2016 ACR/ARHP Annual Meeting
“I Am Always in Pain Somewhere”: Continuing Unmet Need in Rheumatoid Arthritis
Peter C. Taylor¹, Rieke Alten², Juan Jesus Gomez-Reino³, Roberto Caporali⁴, Philippe Bertin⁵, Laura Grant⁶, Elaine Brohan⁶, Jane Wells⁶, Radu Vasilescu⁷ and Miriam Tarallo⁸, ¹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ²Charité University Medicine, Berlin, Germany, ³Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, ⁴Università di Pavia, Pavia, Italy, ⁵Rheumatology, CHU Dupuytren, Limoges, France, ⁶Adelphi Values, Bollington, United Kingdom, ⁷Medical Affairs, Pfizer, Brussels, Belgium, ⁸GHV, Pfizer, Rome, Italy
Background/Purpose: Despite advances in the RA treatment, substantial humanistic and economic burdens remain. This study of patients with RA, with moderate to severe disease activity…
Abstract Number: 1616 • 2016 ACR/ARHP Annual Meeting
Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-α Monoclonal Antibody: Long-Term Safety and Efficacy for up to 158 Weeks of Treatment in Patients with Rheumatoid Arthritis
GR Burmester¹, IB McInnes², JM Kremer³, P Miranda⁴, J Vencovský⁵, A Godwood⁶, M Albulescu⁶, D Close^⁶ and Michael Weinblatt⁷, ¹Charité – University Medicine Berlin, Berlin, Germany, ²University of Glasgow, Glasgow, United Kingdom, ³The Albany Medical College, Albany, NY, ⁴Centro De Estudios Reumatológicos, Santiago, Chile, ⁵Charles University, Prague, Czech Republic, ⁶MedImmune, Cambridge, United Kingdom, ⁷Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Inhibition of GM–CSFR-α is a novel approach to treat RA. Mavrilimumab, an investigational human monoclonal antibody targeting GM–CSFR-α, has demonstrated efficacy and an acceptable…
Abstract Number: 1618 • 2016 ACR/ARHP Annual Meeting
Leflunomide, Sulfasalazine and Hydroxychloroquine for Rheumatoid Arthritis: Efficacious but Poorly Tolerated
Kyle A. Register¹, Amy C. Cannella², Ted R. Mikuls³ and James R. O'Dell⁴, ¹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ²Section of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The combination of methotrexate (MTX), sulfasalazine (SSZ) and hydroxychloroquine (HCQ) (triple therapy) is a highly effective and well-tolerated treatment in rheumatoid arthritis (RA). While…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.